PDCD1 and esophageal squamous cell carcinoma: Fifth, as second-line treatment with PD-1 inhibitors exclusively involves single-agent regimens, our discussion focuses solely on the efficacy and safety of single-agent PD-1 inhibitors for ESCC as second-line therapy, without addressing combination immunotherapy.